论文部分内容阅读
目的对比口服泼尼松与雾化吸入布地奈德治疗慢性阻塞性肺病(COPD)急性加重期患者的疗效。方法将95例COPD急性加重期患者随机分成三组：布地奈德组32例，给予布地奈德混悬液6mg/d，每8h一次雾化吸入治疗；泼尼松龙组31例，给予泼尼松40mg/d，2次/d口服；对照组不使用任何激素。三组其他标准治疗相同。比较三组患者治疗前、以及治疗1d后、3d后、5d后的肺功能指标FEV1/预计值和血气指标PaO2，PaCO2以及治疗有效率和副作用。结果①三组患者治疗前相关指标无明显差异。②治疗3d后，泼尼松组与布地奈德组FEV1/预计值较基础值显著提高，差异具有统计学意义(<0.05)；③治疗3d后，泼尼松组PaO2较基础值明显升高，差异具有统计学意义(<0.05)；治疗3d后，泼尼松组及布地奈德组PaCO2较基础值显著改善(0.05)；④泼尼松组、布地奈德组治疗有效率明显高于对照组，差异具有统计学意义(<0.05)。布地奈德组在副作用方面与对照组无明显差异，少于泼尼松组。结论雾化吸入布地奈德对于COPD急性加重期患者，疗效确切，且副作用少。“,”Objective To evaluate the ef ect of nebulized budesonide and oral prednisone in treatment of chronic obstructive pulmonary disease (C0PD). Methods 95 patients with acute exacerbation of COPD were randomly divided into three groups, budesonide group 32 case, Given budesonide nebulised for 6mg/days, every8 hours,Prednisolone group 31 cases, given oral prednisone 40mg/day, 2 times a day.placebo-control ed group did not use any glucocorticoid.Three groups of ootherth standard treatment are the same.Comparison of The ef iciency and side ef ects,the blood gas indexes of Pa02, PaC02 and FEV1 (Forced expiratory volume in one second )/expectd value, in three groups of patients before treatment, and treatment after 1 days, 3 days, 5 days. Results ①There is no significant dif erence between the three groups of patients before treatment related index. ②After 3 daystreatment, the FEV1/expected value of prednisone group became bet er than before treatment, the dif erence is significantly ( 0.05);③For PaO2, after 3 daystreatment, theprednisone group became bet er than before treatment, the dif erence is significantly ( <0.05);For PaCO2, after 3 daystreatment the PaCO2 of prednisone group and budesonide group were significantly bet er than before treatment, the dif erence was significantly ( 0.05);④The treatment ef ective rate of prednisone group and the budesonidegroup were significantly higher than the control group, with significant dif erence ( <0.05). Budesonide group in the side ef ects and control groups showed no significant dif erence, less than the prednisone group. Conclusion Nebulised atomize budesonide in acute exacerbation of COPD, curative ef ect, less side ef ects.